Anxiety Disorders: University of California San Diego

Stein MB. · Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA. · J Clin Psychiatry. · Pubmed #15384930 No free full text.

Abstract: Generalized anxiety disorder (GAD) is a chronic condition characterized by worry and concomitant anxiety symptoms that cause extreme distress and/or interfere with function. The 12-month prevalence of GAD in the general population ranges in studies from approximately 2% to 5%, with the majority of cases occurring comorbid with major depression. GAD is particularly prevalent in certain special populations, such as older adults, in whom it is the most common anxiety disorder. In clinical and community studies, GAD emerges as a strong predictor of functional impairment, over and above that explained by major depression. These observations lead to the conclusion that current public health efforts focused on identification and treatment of major depression should be extended to include GAD and other anxiety disorders.

Shannahoff-Khalsa DS. · The Research Group for Mind-Body Dynamics, Institute for Nonlinear Science, University of California, San Diego, La Jolla, 92093-0402, USA. · J Altern Complement Med. · Pubmed #15025884 No free full text.

Abstract: The ancient system of Kundalini yoga includes a vast array of meditation techniques and many were discovered to be specific for treating the psychiatric disorders as we know them today. One such technique was found to be specific for treating obsessive-compulsive disorder (OCD), the fourth most common psychiatric disorder, and the tenth most disabling disorder worldwide. Two published clinical trials are described here for treating OCD using a specific Kundalini yoga protocol. This OCD protocol also includes techniques that are useful for a wide range of anxiety disorders, as well as a technique specific for learning to manage fear, one for tranquilizing an angry mind, one for meeting mental challenges, and one for turning negative thoughts into positive thoughts. Part of that protocol is included here and published in detail elsewhere. In addition, a number of other disorder-specific meditation techniques are included here to help bring these tools to the attention of the medical and scientific community. These techniques are specific for phobias, addictive and substance abuse disorders, major depressive disorders, dyslexia, grief, insomnia and other sleep disorders.

Stein MB. · University of California, San Diego, La Jolla 92037, USA. · J Clin Psychiatry. · Pubmed #14658989 No free full text.

Abstract: Anxiety disorders are highly prevalent among patients in primary care. These conditions can be disabling and costly to the patient and to the health care system. Despite the prevalence of anxiety disorders, however, patients often remain undiagnosed and untreated, and patients with unrecognized anxiety disorders tend to be high users of general medical care. Diagnosis may be complicated by the typical presentation in primary care; patients with anxiety disorders may present with multiple somatic complaints and comorbid disorders, causing great effort and expense in identifying the cause of unexplained symptoms. Once anxiety disorders are identified, patients may be treated using well-tested and efficacious psychosocial and pharmacologic treatments. It is therefore important for primary care physicians to recognize and treat patients with anxiety disorders.

Stein MB. · Department of Psychiatry, University of California-San Diego, La Jolla, CA 92037, USA. · Psychopharmacol Bull. · Pubmed #14566205 links to  free full text

Abstract: Social anxiety disorder frequently begins in early life and is associated with the subsequent development of comorbid conditions such as depressive and substance use disorders. Social anxiety disorder, particularly the generalized subtype, is characterized by marked impairment in numerous functional domains, including education and social relations. Paroxetine, the first medication to receive an indication in the United States for the treatment of social anxiety disorder, has been shown to be effective in 50% to 60% of patients. The mechanism of action of paroxetine in the treatment of social anxiety disorder is at present unclear. A possible role for early treatment to prevent complications of social anxiety disorder should be explored.

Moreau C, Zisook S. · Department of Psychiatry, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0603 R, USA. · Psychiatr Clin North Am. · Pubmed #12462860 No free full text.

Abstract: An understanding of PTSD and stress-related conditions is in its infancy. This is not surprising given the fact PTSD was not recognized as a distinct diagnostic entity until 1980. Since that time, the diagnostic classification has undergone continuous change as our understanding of PTSD is refined. The authors believe that PTSD can be best understood through a dimensional conceptualization viewed along at least three spectra: (1) symptom severity, (2) the nature of the stressor, and (3) responses to trauma. Along the severity spectrum, studies that review diagnostic thresholds reveal significant prevalence of PTSD symptoms and impairment that results from subthreshold conditions. Comorbidity patterns suggest that when PTSD is associated with other psychiatric illness, diagnosis is more difficult and the overall severity of PTSD is considerably greater. With regard to a stressor criteria spectrum, the diagnostic nomenclature initially only recognized severe forms of trauma personally experienced. More recently, however, the person's subjective response and events occurring to loved ones were included. This has greatly broadened the stressor criteria by leading to an appreciation of the range of precipitating stressors and the potential impact of "low-magnitude" events. Given that responses to trauma vary considerably, another possible spectrum includes trauma-related conditions. Traumatic grief, somatization, acute stress disorder and dissociation, personality disorders, depressive disorders, and other anxiety disorders all have significant associations with PTSD. Further research is needed to clarify and expand the current understanding of PTSD and other trauma-related conditions. Consideration of the severity of symptoms and the range of stressors coupled with the various disorders precipitated by trauma should greatly influence scientific research. The future undoubtedly will bring a refinement of the current understanding of PTSD and improved treatments.

Akiskal HS, Brieger P, Mundt C, Angst J, Marneros A. · International Mood Centre, Department of Psychiatry, University of California at San Diego, USA. · Nervenarzt. · Pubmed #11963262 No free full text.

Abstract: In temperament research, three traditions can be found: (1) in psychiatry or psychopathology, (2) in neurobiology, and (3) in developmental psychology. After giving an overview, we present results and theories concerning the relation between temperament and affective disorders. Based on Kraepelin's concept of the fundamental states ("Grundszustände"), we describe four types of temperament: hyperthymic (manic), depressive, irritable, and cyclothymic. A fifth anxious temperament is added. Clinical description and scientific implications are described in the light of recent work by Akiskal and the German version of the TEMPS-A scale, a self-report questionnaire for assessing temperament.

Stein MB, Chavira DA, Jang KL. · Department of Psychiatry, University of California, San Diego, La Jolla, California, USA. · Psychiatr Clin North Am. · Pubmed #11723626 No free full text.

Abstract: Shyness is a risk factor for, or an early manifestation of, more enduring problems with social anxiety. But the majority of shy children do not develop social phobia, and factors that further increase risk are poorly understood, underscoring the complexity of this relationship. Studies uniformly show that social phobia (particularly the generalized subtype) runs in families, and twin studies suggest that a moderate component of this familial tendency is genetic in origin. Understanding the genetic etiology of other neuropsychiatric disorders characterized by abnormal social interest, social communication (e.g., autism), or both may prove informative for social phobia. The contribution of unique experiences to the development of social phobia is clear from genetic studies, but studies to date have failed to elucidate what kinds of experiences might be involved. Given patient reports that socially traumatic conditioning experiences have often occurred, detailed evaluation of these kinds of experiences in monozygotic twins discordant for social phobia would be a particularly informative research strategy. Nongenetic familial factors probably have more limited effects on the development of social phobia, although the impact of parental modeling of, and acquiescence to, childhood social fears deserves to be further investigated. These factors may be particularly salient for the expression of social phobia in children whose genes render them susceptible. If so, it should be possible to design early interventions to prevent the progression from phobia proneness (e.g., designated on the basis of family history) to phobic disorder.

Rapaport MH. · Department of Psychiatry, University of California, and the San Diego Veterans Affairs Healthcare System, 92037, USA. · J Clin Psychiatry. · Pubmed #11676431 No free full text.

Abstract: The management of depression is often complicated by comorbid psychiatric illness. Incomplete diagnoses or inadequate treatment can severely limit a patient's improvement. However, careful diagnosis and straightforward treatment can relieve suffering and restore function. This article will examine recent research investigating the coexistence of depression with a number of different anxiety disorders and review literature on the prevalence and recognition of depression with comorbid anxiety disorders. Finally, current data on treatment will be discussed, with a focus on optimal treatment approaches and duration of treatment.

Ancoli-Israel S. · Department of Psychiatry, Veterans Affairs, San Diego Healthcare System, San Diego, California 92161, USA. · Psychosom Med. · Pubmed #11573026 links to  free full text

Abstract: Much of what is known about sleep disorders has been uncovered in the last forty years. As scientists, we consider these discoveries to be landmarks. Yet there is a tremendous amount of information written about sleep in the Bible and its commentaries. Sleep, and even sleep disorders, are referred to in many instances and can be directly interpreted by what we know today. Our forefathers and foremothers generally viewed sleep as both pleasant and necessary and were aware that sleep was not one continuous stage. They referred to the function of sleep as being restorative. They deplored sleep deprivation, believing that it impaired life. They felt that excessive sleepiness was harmful. They understood that insomnia could be caused by stress and anxiety and by excessive alcohol, and that physical activity (exercise) and drinking milk could improve sleep. They suggested cures for insomnia, including some of the ideas included in today's sleep hygiene rules. They understood that there was a rhythm or timing to sleep. They even understood that it is easier to delay the circadian rhythm that to advance it. Although naps are not recommended, they sometimes took naps in the afternoon, but suggested just how long that nap should last-about one-half hour. And they knew that with age, although sleep is advanced, healthy elderly do not have difficulty sleeping. Although we think we have discovered many new features about sleep disorders, much of what we know today was suggested thousands of years ago and documented in the Bible and the Talmud.

Sable JA, Jeste DV. · University of California, San Diego VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, CA 92161, USA. · Curr Psychiatry Rep. · Pubmed #11470037 No free full text.

Abstract: In the population of older adults, anxiety disorders are underdiagnosed and undertreated. Epidemiologic studies have generally found that the prevalence of anxiety disorders declines with age. Recognition of anxiety disorders in older adults is, however, complicated by several age-related factors including the presence of depression, cognitive impairment, and physical illness. A variety of medications have been used to treat anxiety disorders across the life span; however, few studies have evaluated their use specifically in older adults. Choice of medication requires consideration of the effects of aging on safety, tolerability, and adherence. Available data suggest that cognitive and behavioral treatments may be effective for anxiety disorders in older adults. Appropriate medical evaluation and psychosocial interventions are recommended prior to initiating pharmacotherapy. When pharmacologic treatment is warranted, antidepressant medications at low doses may be useful for late-life anxiety disorders; other agents may be considered for augmentation or second-line use in certain types of patients.

Rapaport MH, Barrett C. · Department of Psychiatry, University of California at San Diego and Psychiatric Service San Diego Veterans Affairs Healthcare System, 8950 La Jolla Drive, La Jolla, CA 92037, USA. · Curr Psychiatry Rep. · Pubmed #11470036 No free full text.

Abstract: In this article, the authors review the most recent advances in the pharmacotherapy, psychotherapy, and combined therapy for panic disorder. The authors focus on peer-reviewed data and on pragmatic clinical approaches that may help patients suffering from panic disorder.

Seedat S, Stein MB. · Department of Psychiatry (0985), University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, USA. · Curr Psychiatry Rep. · Pubmed #11470035 No free full text.

Abstract: This article provides an update on recent findings in post-traumatic stress disorder (PTSD) with reference to pertinent epidemiologic, etiologic, diagnostic, and treatment advances in the past year. New studies serve to confirm high prevalence rates in the general population (7% to 12%), and high rates of secondary mood, anxiety, and substance use disorders. Recent substantive evidence has highlighted 1) the unique pattern of biological alteration in PTSD that distinguishes it from the normative stress response, and 2) the role of constitutional risk factors and trauma-related factors in determining disease expression after trauma exposure. The emergence of consistent data suggesting that medications (selective serotonin reuptake inhibitors) and psychotherapies (cognitive-behavior therapy) are effective in reducing core symptoms and improving quality of life, has reinforced optimism and more widespread use of these interventions in patients with PTSD.

Stein MB, Gorman JM. · Department of Psychiatry (0985), University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0985, USA. · J Psychiatry Neurosci. · Pubmed #11394188 links to  free full text

This publication has no abstract.

Lang AJ, Stein MB. · Department of Psychiatry, University of California, San Diego, USA. · Geriatrics. · Pubmed #11373949 No free full text.

Abstract: Anxiety symptoms in older patients frequently coexist with depression, medical illness, and dementia, which complicate diagnosis and treatment. Most anxiety disorders do not begin in later life but are a recurrence or worsening of a pre-existing condition. Anxiety should be considered in any older patient with depressive symptoms or somatic complaints that are not explained by physical examination. Older patients may benefit from cognitive-behavioral therapy and relaxation training. Antidepresants, particularly selective serotonin reuptake inhibitors, are the preferred medical treatment.

Swerdlow NR. · Department of Psychiatry, University of California, San Diego, La Jolla, California, USA. · Med Clin North Am. · Pubmed #11349482 No free full text.

Abstract: The phenomenology of OCD and TS seem to match perfectly with the existing conceptualization of the functional relationship between frontal cortical and subcortical circuits. Failed editing of thoughts and impulses, perseverative patterns, and inhibitory deficits are the most convenient descriptors of the symptoms, and some operationalized measures can capture evidence for such deficits in TS and OCD patients. Beyond these expectations borne from conceptual models and some broad patterns of distributed metabolic disturbances in neuroimaging studies, a specific causal pathology within CSPT circuitry needs to be identified in these disorders. This is not a criticism of the existing studies of TS and OCD; to the contrary, the scarcity of pathologic material, the limits of resolution of existing technologies, and the heterogeneity of the phenotypes make the accomplishments of these studies more impressive. As clinicians strive to integrate clinical and scientific findings into coherent models for the pathophysiology of OCD and TS, it is useful to identify practical and effective strategies for therapeutic interventions.

Lang AJ, Stein MB. · Department of Psychiatry, University of California San Diego and VA San Diego Healthcare System, USA. · J Clin Psychiatry. · Pubmed #11206034 No free full text.

Abstract: This article reviews the literature on the prevalence and demographic features of social phobia in both community and general medical settings. The age at onset of social phobia is examined, as are comorbid conditions. Important differences between social phobia as it appears in the community and in primary care settings are explored. We conclude that social phobia is common and associated with significant impairment in a number of life areas. We discuss the diagnostic threshold of social phobia and potential difficulties in differentiating this disorder from other mental disorders.

Chavira DA, Stein MB. · Department of Psychiatry, University of California at San Diego, Box 0985, 9500 Gilman Drive, La Jolla, CA 92093-0985, USA. · Curr Psychiatry Rep. · Pubmed #11122980 No free full text.

Abstract: The following article discusses research trends in childhood and adolescent social phobia during the past year. Of particular importance are findings regarding prevalence rates, cognitive variables and social skills deficits, temperamental influences, and the use of selective serotonin reuptake inhibitors (SSRIs). Recent prevalence rates of social anxiety disorder in children and adolescents range from 0.5% to 4.0%. Findings regarding the role of cognitive processes and social skills deficits in childhood social phobia are supported. Recent longitudinal data investigating the stability of extremes of behavioral inhibition have found that it persists from childhood into adolescence. Initial data regarding the use of SSRIs suggest that they may be a promising treatment option.

Akiskal HS, Bourgeois ML, Angst J, Post R, Möller H, Hirschfeld R. · International Mood Center, University of California at San Diego, La Jolla, CA, USA. · J Affect Disord. · Pubmed #11121824 No free full text.

Abstract: Until recently it was believed that no more than 1% of the general population has bipolar disorder. Emerging transatlantic data are beginning to provide converging evidence for a higher prevalence of up to at least 5%. Manic states, even those with mood-incongruent features, as well as mixed (dysphoric) mania, are now formally included in both ICD-10 and DSM-IV. Mixed states occur in an average of 40% of bipolar patients over a lifetime; current evidence supports a broader definition of mixed states consisting of full-blown mania with two or more concomitant depressive symptoms. The largest increase in prevalence rates, however, is accounted for by 'softer' clinical expressions of bipolarity situated between the extremes of full-blown bipolar disorder where the person has at least one manic episode (bipolar I) and strictly defined unipolar major depressive disorder without personal or family history for excited periods. Bipolar II is the prototype for these intermediary conditions with major depressions and history of spontaneous hypomanic episodes; current evidence indicates that most hypomanias pursue a recurrent course and that their usual duration is 1-3 days, falling below the arbitrary 4-day cutoff required in DSM-IV. Depressions with antidepressant-associated hypomania (sometimes referred to as bipolar III) also appear, on the basis of extensive international research neglected by both ICD-10 and DSM-IV, to belong to the clinical spectrum of bipolar disorders. Broadly defined, the bipolar spectrum in studies conducted during the last decade accounts for 30-55% of all major depressions. Rapid-cycling, defined as alternation of depressive and excited (at least four per year), more often arise from a bipolar II than a bipolar I baseline; such cycling does not in the main appear to be a distinct clinical subtype - but rather a transient complication in 20% in the long-term course of bipolar disorder. Major depressions superimposed on cyclothymic oscillations represent a more severe variant of bipolar II, often mistaken for borderline or other personality disorders in the dramatic cluster. Moreover, atypical depressive features with reversed vegetative signs, anxiety states, as well as alcohol and substance abuse comorbidity, is common in these and other bipolar patients. The proper recognition of the entire clinical spectrum of bipolarity behind such 'masks' has important implications for psychiatric research and practice. Conditions which require further investigation include: (1) major depressive episodes where hyperthymic traits - lifelong hypomanic features without discrete hypomanic episodes - dominate the intermorbid or premorbid phases; and (2) depressive mixed states consisting of few hypomanic symptoms (i.e., racing thoughts, sexual arousal) during full-blown major depressive episodes - included in Kraepelin's schema of mixed states, but excluded by DSM-IV. These do not exhaust all potential diagnostic entities for possible inclusion in the clinical spectrum of bipolar disorders: the present review did not consider cyclic, seasonal, irritable-dysphoric or otherwise impulse-ridden, intermittently explosive or agitated psychiatric conditions for which the bipolar connection is less established. The concept of bipolar spectrum as used herein denotes overlapping clinical expressions, without necessarily implying underlying genetic homogeneity. In the course of the illness of the same patient, one often observes the varied manifestations described above - whether they be formal diagnostic categories or those which have remained outside the official nosology. Some form of life charting of illness with colored graphic representation of episodes, stressors, and treatments received can be used to document the uniquely varied course characteristic of each patient, thereby greatly enhancing clinical evaluation.

Grimes AL, McCullough LB, Kunik ME, Molinari V, Workman RH. · Department of Psychiatry, University of California, San Diego, CA, USA. · Psychiatr Serv. · Pubmed #11097654 links to  free full text

Abstract: The authors examine the less-studied components of patients' autonomous decision making, or decisional autonomy, in the light of current research in psychiatry and neuropsychology and developments in the construct of informed consent. The three components of decisional autonomy-understanding, intentionality, and noncontrol or voluntariness-are related to clinical constructs in psychiatry and neuropsychology, in particular to executive control functions. The authors review studies that examine deficits in prefrontal cerebral function in schizophrenia, depression, and some anxiety disorders that are related to intentionality and voluntariness. Assessment of decisional autonomy should encompass evaluation of impaired intentionality and voluntariness, not simply impaired understanding. The main response to finding such impairments should be to provide treatment to ameliorate them. New strategies for psychiatric care should be developed to address the clinical challenges of an increasingly complex view of decisional autonomy.

Mendlowicz MV, Stein MB. · Department of Psychiatry, University of California at San Diego, La Jolla, CA 92037, USA. · Am J Psychiatry. · Pubmed #10784456 links to  free full text

Abstract: OBJECTIVE: Quality-of-life indices have been used in medical practice to estimate the impact of different diseases on functioning and well-being and to compare outcomes between different treatment modalities. An integrated view of the issue of quality of life in patients with anxiety disorders can provide important information regarding the nature and extent of the burden associated with these disorders and may be useful in the development of strategies to deal with it. METHOD: A review of epidemiological and clinical studies that have investigated quality of life (broadly conceptualized) in patients with panic disorder, social phobia, posttraumatic stress disorder, generalized anxiety disorder, and obsessive-compulsive disorder was conducted by searching MEDLINE and PsycLIT citations from 1984 to 1999. A summary of the key articles published in this area is presented. RESULTS: The studies reviewed portray an almost uniform picture of anxiety disorders as illnesses that markedly compromise quality of life and psychosocial functioning. Significant impairment can also be found in individuals with subthreshold forms of anxiety disorders. Effective pharmacological or psychotherapeutic treatment has been shown to improve the quality of life for patients with panic disorder, social phobia, and posttraumatic stress disorder. Limitations in current knowledge in this area are identified, and suggestions for needed future research are provided. CONCLUSIONS: It is expected that a more thorough understanding of the impact on quality of life will lead to increased public awareness of anxiety disorders as serious mental disorders worthy of further investment in research, prevention, and treatment.

Sareen L, Stein M. · Department of Psychiatry, University of California San Diego, La Jolla 92093-0985, USA. · Drugs. · Pubmed #10776832 No free full text.

Abstract: This review presents current literature on the epidemiology and treatment of social anxiety disorder (social phobia). This illness has been demonstrated to be the most common anxiety disorder with a 1-year prevalence of 7 to 8% and a lifetime prevalence of 13 to 14% in patients aged between 15 and 54 years. Social anxiety disorder can be classified into 2 subtypes, discrete and generalised. Morbidity is high with this disorder, and 70 to 80% of patients have co-morbid mental disorders. Although effective treatments are available, social anxiety disorder is under-recognised and under-treated. Treatments that have been systemically studied and have shown efficacy in patients with social anxiety disorder include pharmacotherapy (selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, reversible inhibitors of monoamine-A and benzodiazepines) and short term psychotherapies (cognitive behaviour therapy, social skills training and exposure in vivo therapy). Beta-blockers are useful in treating performance-related anxiety. Few published data are available on the treatment of social anxiety disorder with a combination of pharmacotherapy and psychotherapy. We conclude this review by discussing proposed algorithms for treating both subtypes of social anxiety disorder.

Moutier CY, Stein MB. · Anxiety and Traumatic Stress Disorders Research Program, University of California, San Diego, La Jolla 92037, USA. · J Clin Psychiatry. · Pubmed #10335673 No free full text.

Abstract: Social anxiety disorder has only recently garnered recognition as a unique anxiety disorder. Although social anxiety disorder is distinguishable from other psychiatric disorders, there are several areas in which this distinction is not straightforward. Furthermore, social anxiety disorder is associated with considerable comorbidity with other disorders, which may render differential diagnosis a challenging endeavor. This article will review those disorders that must be differentiated from social anxiety disorder, including major depression, panic disorder with agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, and body dysmorphic disorder. In addition, the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) provides specific examples of disorders, e.g., verbal dysfluency (stuttering) and Parkinson's disease, in the context of which social anxiety disorder is not to be diagnosed. Social anxiety disorder is also frequently comorbid with the Axis II avoidant personality disorder. Interestingly, this may present a prime example of "comorbidity by committee," because it is growing increasingly clear that much avoidant personality disorder as defined by DSM-IV merely denotes a subgroup of patients with generalized social anxiety disorder. Because social anxiety disorder has a chronic course and is associated with significant morbidity, it is critical that patients receive an accurate diagnosis and appropriate treatment.

Saxena S, Brody AL, Maidment KM, Baxter LR. · UCSD Department of Psychiatry, VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, CA 92161, USA. · J Psychiatr Res. · Pubmed #16790250 No free full text.

Abstract: OBJECTIVE: Compulsive hoarding, found in many patients with obsessive-compulsive disorder (OCD), has been associated with poor response to serotonin reuptake inhibitor (SRI) medications in some reports. However, no prior study has quantitatively measured response to standardized pharmacotherapy in compulsive hoarders. We sought to determine whether compulsive hoarders would respond as well as non-hoarding OCD patients to the SRI, paroxetine. METHODS: Seventy-nine patients with OCD (32 patients with the compulsive hoarding syndrome and 47 patients without prominent hoarding symptoms) were treated openly with paroxetine (mean dose 41.6+/-12.8 mg/day; mean duration 80.4+/-23.5 days) according to a standardized protocol, from 3/1993 to 7/2005. All subjects were free of psychotropic medication for at least four weeks prior to study entry. No psychotherapy or psychotropic medications except paroxetine were allowed during the study period. Subjects were assessed before and after treatment with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Scale (Ham-A), Global Assessment Scale (GAS), and Clinical Global Impression/Improvement (CGI) scale. RESULTS: Both compulsive hoarders and non-hoarding OCD patients improved significantly with treatment (p<0.001), with nearly identical changes in Y-BOCS, HDRS, Ham-A, and GAS scores. There were no significant differences between groups in the proportions of patients who completed or responded to treatment. Hoarding symptoms improved as much as other OCD symptoms. CONCLUSIONS: Compulsive hoarders responded as well to paroxetine treatment as non-hoarding OCD patients, suggesting that SRI medications are effective for compulsive hoarding. Controlled trials of SRI medications for compulsive hoarding are now warranted.

Paulus MP, Feinstein JS, Castillo G, Simmons AN, Stein MB. · Laboratory of Biological Dynamics and Theoretical Medicine and Department of Psychiatry, University of California, San Diego, USA. · Arch Gen Psychiatry. · Pubmed #15753241 links to  free full text

Abstract: BACKGROUND: Functional neuroimaging may elucidate the pathophysiologic features of anxiety disorders and the site of action of anxiolytic drugs. A large body of evidence suggests that the amygdala and associated limbic structures play a critical role in the expression of anxiety and may be treatment targets for anxiolytic drugs. OBJECTIVE: To determine whether lorazepam dose-dependently attenuates blood oxygenation level-dependent functional magnetic resonance imaging (BOLD fMRI) activation in the amygdala and associated limbic structures during an emotion face assessment task. PARTICIPANTS AND DESIGN: Fifteen healthy volunteers participated in a double-blind, placebo-controlled, randomized dose-response study. Subjects underwent imaging 3 times (at least a week apart) and were given either a single-dose placebo or 0.25 mg or 1.0 mg of lorazepam 1 hour prior to an MRI session. During fMRI, subjects completed an emotion face assessment task, which has been shown to elicit amygdala activation. MAIN OUTCOME MEASURES: The BOLD-fMRI activation in amygdala, insula, and medial prefrontal cortex during the emotion face assessment task. RESULTS: Lorazepam significantly attenuated the BOLD-fMRI signal in a dose-dependent manner in bilateral amygdala and insula but not in the medial prefrontal cortex. Lorazepam did not affect the BOLD-fMRI signal in the primary visual cortex. CONCLUSIONS: The current finding provides the first neuroimaging evidence of a dose-dependent change induced by an established therapeutic agent in brain regions known to be critical for the mediation of anxiety. This investigation may help to support the use of BOLD-fMRI with pharmacological probes to investigate the neural circuits underlying anxiety and the use of fMRI as a tool in the development of new anxiolytic agents.

Stein MT, Heyneman EK, Stern EJ. · Professor of Pediatrics, University of California San Diego, Children's Hospital, California, USA. · J Dev Behav Pediatr. · Pubmed #15613991 No free full text.

This publication has no abstract.